📖 Your Q2 Earnings Guide: Discover the Stocks ProPicks AI Highlights to Jump Post-EarningsRead more

J&J makes takeover approach for Swiss drugmaker Actelion: Bloomberg

Published 11/24/2016, 02:42 PM
Updated 11/24/2016, 02:50 PM
© Reuters. A general view shows Swiss biotech group Actelion Headquarters in Allschwil

(Reuters) - U.S. healthcare company Johnson & Johnson (N:JNJ) has approached Swiss biotechnology firm Actelion Ltd (S:ATLN) about a potential takeover, Bloomberg reported on Thursday, citing people it said were familiar with the matter.

The report said that deliberations are still at an early stage following Johnson & Johnson's initial offer, and Actelion is working with an adviser to explore options.

Johnson & Johnson Chief Executive Alex Gorsky said earlier this year that the company was interested in making deals to expand its main consumer, medical device, and pharmaceuticals segments. He noted that in recent years, J&J had derived about half its revenue from acquired products.

Johnson & Johnson agreed to buy Abbott Laboratories' (N:ABT) eye care business for about $4.33 billion in cash in September.

Actelion shares have risen more than 13 percent this year, valuing it at about $17 billion.

In October, Actelion raised its earnings guidance for the third time this year as sales from its new drugs Opsumit and Uptravi, which treat pulmonary arterial hypertension (PAH), for the first time surpassed those of Tracleer, its decade-long mainstay that lost U.S. patent protection last November.

© Reuters. A general view shows Swiss biotech group Actelion Headquarters in Allschwil

Johnson & Johnson and Actelion were not immediately available for comment.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.